Bank of America Securities analyst Geoff Meacham maintained a Buy rating on Caribou Biosciences (CRBU – Research Report) today. The company’s shares opened today at $3.74.
Meacham covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Eli Lilly & Co, and Moderna. According to TipRanks, Meacham has an average return of 3.0% and a 49.46% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Caribou Biosciences with a $20.75 average price target, which is a 454.81% upside from current levels. In a report released on May 10, H.C. Wainwright also reiterated a Buy rating on the stock with a $24.00 price target.
The company has a one-year high of $8.59 and a one-year low of $3.44. Currently, Caribou Biosciences has an average volume of 1.62M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Caribou Biosciences (CRBU) Company Description:
Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies.
Read More on CRBU:
- Caribou Biosciences reports Q1 EPS (46c), consensus (41c)
- Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
- Caribou Biosciences Advances with FDA Clearance and New Trials
- FDA clears Caribou’s IND application for CB-010 to treat lupus and ERL
